Skip to Content

T. Rowe Price Health Sciences PRHSX

Medalist Rating as of | See T. Rowe Price Investment Hub
  • NAV / 1-Day Return 98.11  /  −0.30 %
  • Total Assets 15.4 Bil
  • Adj. Expense Ratio
    0.800%
  • Expense Ratio 0.800%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 48%

USD | NAV as of Jul 15, 2024 | 1-Day Return as of Jul 15, 2024, 10:18 PM GMT+0

Morningstar’s Analysis PRHSX

Will PRHSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A healthcare fund with merit.

Senior Analyst Adam Sabban

Adam Sabban

Senior Analyst

Summary

The T. Rowe Price Health Sciences strategy is among the better options available given its strong investment resources, research depth, and framework.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PRHSX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 50.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.92 1.5 Bil
Healthcare

Aggregate Miscellaneous Equity

9.49 1.5 Bil

UnitedHealth Group Inc

6.07 936.0 Mil
Healthcare

Intuitive Surgical Inc

4.13 636.2 Mil
Healthcare

Thermo Fisher Scientific Inc

4.04 623.0 Mil
Healthcare

Merck & Co Inc

4.04 622.2 Mil
Healthcare

Stryker Corp

3.64 561.6 Mil
Healthcare

Elevance Health Inc

3.55 547.8 Mil
Healthcare

Danaher Corp

2.96 456.1 Mil
Healthcare

Regeneron Pharmaceuticals Inc

2.69 414.6 Mil
Healthcare